SEARCH

SEARCH BY CITATION

References

  • 1
    Hughes GRV: The antiphospholipid syndrome: ten years on. Lancet 342: 341344, 1993
  • 2
    Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J, Dutt HH, Harris EN, Villardel-Torres M, Hughes GRV: The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68: 366374, 1989
  • 3
    Malia RG, Kitchen S, Greaves M, Preston E: Inhibition of activated protein C and its cofactor S by antiphospholipid antibodies. Br J Haematol 76: 101107, 1990
  • 4
    Borrell M, Sala N, de Castellarnau C, López S, Gari M, Fontcuberta J: Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 68: 268272, 1992
  • 5
    Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO: Imbalance of thromboxane/prostacyclin biosyntesis in patients with lupus anticoagulant. Blood 78: 28942899, 1991
  • 6
    Watson TS, Schorer AE: Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 90: 4753, 1991
  • 7
    Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vázquez JJ, Hughes GRV: Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 47: 849854, 1988
  • 8
    Edgington TS, Mackman N, Brank K, Ruf W: The structural biology of expression and function of tissue factor. Thromb Haemost 66: 6779, 1991
  • 9
    Nemerson Y: Tissue factor and hemostasis. Blood 71: 18, 1988
  • 10
    Harris EN, Baguley E, Asherson RA, Hughes GRV: Clinical and serological features of the antiphospholipid syndrome (APS) (abstract). Br J Rheumatol 26: 19, 1987
  • 11
    National Institute of Neurological Disorders and Stroke: Special report: classification of cerebrovascular diseases III. Stroke 21: 637676, 1990
  • 12
    Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 74: 11851190, 1995
  • 13
    Rosove MN, Ismail M, Koziol BJ, Runge A, Kasper CK: Lupus anticoagulants: improved diagnosis with a Kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 68: 472478, 1986
  • 14
    Thiagarajan P, Pengo V, Shapiro SS: The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 68: 869874, 1986
  • 15
    Tripplet DA: Assays for detection of antiphospholipid antibodies. Lupus 3: 281287, 1994
  • 16
    Harris EN, Gharavi AE, Patel SP, Hughes GRV: Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 68: 215222, 1987
  • 17
    Carson S: Continuous chromogenic tissue factor assay comparison to clot-based assays and sensitivity established using pure tissue factor. Br J Haematol 47: 379387, 1987
  • 18
    Carreras LO, Vermylen JG: ‘Lupus’ anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 48: 2840, 1982
  • 19
    Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 70: 667671, 1993
  • 20
    Campbell AL, Pierangeli SS, Wellhausen S, Harris EN: Autoimmune antiphospholipid antibodies enhance activation and aggregation of human platelets in vitro. Thromb Haemost 73: 529534, 1995
  • 21
    Cariou R, Tobelin G, Belluci S, Soria J, Soria C, Maclouf J, Caen J: Effect of the lupus anticoagulant on antithrombogenic properties of endothelial cells: inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 60: 5458, 1985
  • 22
    Marciniak E, Romond ED: Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74: 24262432, 1989
  • 23
    Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG: Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism. Blood 81: 26182625, 1993
  • 24
    Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T: Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179: 457462, 1994
  • 25
    Roubey RAS: Autoantibodies to phospholipid-binding plasma proteins, a new view of lupus anticoagulant and other “antiphospholipid” autoantibodies. Blood 84: 28542867, 1994
  • 26
    Ichikawa K, Khamashta MA, Koike T, Matsuura E, Hughes GRV: β2-glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 37: 14531461, 1994
  • 27
    Rustin MHA, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM: Effects of lupus anticoagulant in patients with lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 90: 744748, 1988
  • 28
    Tannenbaum SH, Finko R, Cines DB: Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137: 15321537, 1986
  • 29
    Branch DW, Rodgers GM: Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 168: 206210, 1993
  • 30
    Brandt JT: The effect of lupus anticoagulant on the expression of tissue factor activity by cultured endothelial cells (abstract). Thromb Haemost 65: 673, 1991
  • 31
    Schved JF, Gris JC, Ollivier V, Wautier JL, Tobelem G, Caen J: Procoagulant activity of endotoxin on TNF activated monocytes is enhanced by IgG from patients with lupus anticoagulant. Am J Hematol 41: 9296, 1992
  • 32
    Kornberg A, Blank M, Kaufman S, Shoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 153: 13281332, 1994
  • 33
    Reverter JC, Tássies D, Font J, Monteagudo J, Escolar G: Hypercoagulable state in patients with the APS is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler Thromb Vasc Biol 16: 13191326, 1996
  • 34
    Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denburg JA: Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 81: 29582963, 1993
  • 35
    Pierangeli S, Wei L Xiao, Baker JH, Anderson G, Harris N: Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost 74: 13611367, 1995
  • 36
    Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV: Thrombosis, recurrent fetal loss and thrombocytopenia: predictive value of the anti-cardiolipin antibody test. Arch Intern Med 146: 21532156, 1986
  • 37
    Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117: 9971002, 1992
  • 38
    Khamashta MA, Cuadrado MJ, Mujic F, Taub N, Hunt BJ, Hughes GRV: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332: 993997, 1995